Proteomics Study by Serum and Platelet With Neurodegeneration Disease Patients

Seoul National University Hospital1 site in 1 country22 target enrollmentMay 2005

ConditionsBiomarker With Neurodegeneration Patients

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Biomarker With Neurodegeneration Patients
Sponsor: Seoul National University Hospital
Enrollment: 22
Locations: 1
Status: Terminated
Last Updated: 10 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

Using to method of Proteomics, for aims to conquer intractable disease, try to access variety experiment. Biomarker is necessary to develop new diagnosis method and target of treatment.

Detailed Description

Following Seoul National University Hospital Institutional Review Board approval, obtain serum and platelet with neurodegeneration patients and control group visited the part of neurology, there'll be analysis to differentiate each other diseases use to method Proteomics. Biomarker will be screening via 1D/2D analysis, Mass analysis, database searching- the MASCOT search tool, SWISS-PROT and etc.

Registry

clinicaltrials.gov

Start Date

May 2005

End Date

January 2014

Last Updated

10 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Seoul National University Hospital

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•neurodegeneration patients and control group include dementia patients visited the part of neurology.
•over the age of 18
•when participants can understand subject of this study
•Total point of Mini Mental state exam(MMSE)should be Under 26 include MCI (mild cognitive impairment) and over GDS score 3points.
•exclusion criteria:
•under eighteen years of age
•when participants cannot understand subject of this study
•cannot accept this study